Tesamorelin, a peptide that nudges the body to release its own growth hormone, reliably shrank the deep abdominal fat that antiretroviral therapy can pile onto people with HIV, according to a pooled analysis of four randomized trials covering 909 patients. The efficacy is not in doubt. What the paper leaves open is whether shrinking that fat compartment is worth the side effects and the dropouts that came with it.
The condition is HIV-associated lipodystrophy, a redistribution of body fat that older and long-running combined antiretroviral therapy can trigger. It packs on visceral adipose tissue, the fat wrapped around the internal organs rather than sitting under the skin. It distresses patients enough that some stop taking the drugs keeping their HIV in check. Tesamorelin, sold as Egrifta by Theratechnologies, is the only drug the FDA has approved for it. The agency cleared the once-daily injection in November 2010. It is an analogue of growth-hormone-releasing hormone, which means it prompts the pituitary to put out more of the body's own growth hormone. That growth hormone in turn drives the breakdown of visceral fat.
What the pooled numbers show
The meta-analysis ↗ was published July 31 in the Journal of the International Association of Providers of AIDS Care. A group of authors across several Pakistani medical schools gathered every randomized controlled trial of tesamorelin in this setting through early February 2026. On the primary fat measure, tesamorelin at 2 mg a day cut visceral adipose tissue by a pooled 21 units on the scale the trials used. Those trials measure that fat as a cross-sectional area in square centimeters on a CT scan. Waist circumference fell by about 1.6 centimeters, trunk fat by 1.2 kilograms, and lean body mass rose by 1.4 kilograms. Patients lost fat and gained a little muscle at the same time. Total cholesterol dropped modestly, by 0.16 millimoles per liter.
Several of those results were remarkably consistent across the trials. Waist circumference, trunk fat, and lean mass all showed no measurable heterogeneity between studies, meaning the trials agreed with each other closely. The visceral-fat number was the noisy one, with high heterogeneity (an I-squared of 74 percent, where higher means the trials disagreed more on the size of the effect).
The cost side of the ledger
Two caveats keep this from being a clean win. The first is that every endpoint here is a body-composition measure, not a health outcome. The trials show tesamorelin moves fat and muscle around; they do not show that doing so lowers heart attacks, improves how long patients stay on their HIV regimen, or holds up over years. The authors flag the thin long-term safety data, the unsettled question of optimal dosing, and the unknown durability once the drug stops.
The second is tolerability. Patients on tesamorelin were more than twice as likely to discontinue treatment (risk ratio 2.25). That difference sat right at the edge of statistical significance rather than clearly crossing it. The confidence interval ran from 0.98 to 5.17, so it just touches the no-difference line. Growth-hormone-related adverse effects are the expected reason, the kind that come with pushing the growth-hormone axis (joint aches, fluid retention, effects on blood sugar). For a drug taken to manage a cosmetic and metabolic complication rather than a life-threatening one, a higher quit rate is not a footnote.
Tesamorelin is a useful counterpoint to the drugs dominating the fat-loss conversation right now. It does not chase overall weight the way the GLP-1 class does. It is aimed at one fat depot, through a different receptor, the growth-hormone-releasing hormone receptor ↗, and its job on the tesamorelin card ↗ is targeted visceral-fat reduction, not appetite. This analysis firms up that it does that job. It also makes the case that the harder questions, whether the fat loss lasts and whether patients will stay on the drug to get it, are the ones the next trials should answer.